Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov;50(13):3817-3819.
doi: 10.1007/s00259-023-06426-7.

Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial

Karl-Josef Langen  1   2   3 , Norbert Galldiks  1   3   4 , Philipp Lohmann  1 , Felix M Mottaghy  5   6   7
Affiliations
Editorial

Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial

Karl-Josef Langen et al. Eur J Nucl Med Mol Imaging. 2023 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

FMM is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis; holds speaker positions at Siemens, GE Healthcare, and Bayer; and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision Healthcare LLC. FMM is supported by the German Research Foundation (DFG) within the framework of the Research Training Group 2375 “Tumor-targeted Drug Delivery” (grant 331065168), the Clinical Research Unit CRU 5011 “Integrating emerging methods to advance translational kidney research (InteraKD)” (project 445703531), and the Research Unit 2591 “Severity assessment in animal-based research” (project 321137804). In addition, his research is funded by German Cancer Aid (projects 70113779 and 70113780) and the German Federal Ministry of Research and Education (project 16GW0319K).

K.-J.L and F.M.M. received honoraria for consultancy service from Telix Pharmaceuticals. P.L. received speaker honoraria from Blue Earth Diagnostics. N.G. received honoraria for lectures from Blue Earth Diagnostics and honoraria for advisory board participation from Telix Pharmaceuticals.

Comment on

References

    1. Galldiks N, Lohmann P, Fink GR, Langen KJ. Amino acid PET in neurooncology. J Nucl Med. 2023;64:693–700. doi: 10.2967/jnumed.122.264859. - DOI - PubMed
    1. Galldiks N, Niyazi M, Grosu AL, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol. 2021;23:881–893. doi: 10.1093/neuonc/noab013. - DOI - PMC - PubMed
    1. Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–557. doi: 10.1007/s00259-018-4207-9. - DOI - PMC - PubMed
    1. Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18:1199–1208. doi: 10.1093/neuonc/now058. - DOI - PMC - PubMed
    1. Galldiks N, Langen KJ, Albert NL, et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. Neuro Oncol. 2019;21:585–595. doi: 10.1093/neuonc/noz003. - DOI - PMC - PubMed